AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Hematopoietic Stem Cell TransplantationStem Cell TransplantationTransplantation, HomologousTransplantation, AutologousStem CellsPeripheral Blood Stem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseBone Marrow TransplantationKidney TransplantationHematologic NeoplasmsLiver TransplantationGraft SurvivalTissue DonorsHematopoietic Stem CellsTreatment OutcomeTransplantation ChimeraMesenchymal Stem Cell TransplantationCord Blood Stem Cell TransplantationCell TransplantationImmunosuppressive AgentsEmbryonic Stem CellsMyeloablative AgonistsHeart TransplantationHistocompatibility TestingGraft RejectionBusulfanRecurrenceRetrospective StudiesAdult Stem CellsLung TransplantationWhole-Body IrradiationMultiple MyelomaCombined Modality TherapyHistocompatibilityMelphalanRemission InductionHematopoietic Stem Cell MobilizationTime FactorsTransplantation ImmunologyTransplantationGraft vs Leukemia EffectLeukemiaPluripotent Stem CellsSurvival RateCell DifferentiationSurvival AnalysisDisease-Free SurvivalVidarabineNeural Stem CellsStem Cell NicheCyclophosphamideAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsMesenchymal Stromal CellsImmunosuppressionHepatic Veno-Occlusive DiseaseTransplantation, IsogeneicHLA AntigensSalvage TherapyFollow-Up StudiesLeukemia, Myeloid, AcuteChimerismGraft vs Tumor EffectTransplantsCytomegalovirus InfectionsLiving DonorsInduced Pluripotent Stem CellsOrgan TransplantationSiblingsHematologic DiseasesIslets of Langerhans TransplantationLymphocyte TransfusionAntilymphocyte SerumCyclosporineMyelodysplastic SyndromesLymphoma, Non-HodgkinMultipotent Stem CellsGranulocyte Colony-Stimulating FactorPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte DepletionBone Marrow CellsPrognosisHematopoiesisAcute DiseaseCell LineageAnemia, AplasticFetal Stem CellsImmunocompromised HostCytarabineHodgkin DiseaseUnrelated DonorsCells, CulturedFetal Tissue TransplantationTissue and Organ ProcurementTransplantation ToleranceTacrolimusStem Cell FactorPancreas Transplantation
BoneChemotherapyOutcomesPost-transplant cyclophosphamideCurativeRecipientsHSCTPatientsCyclophosphamideHaploidentical transplantationUmbilicalAllogeneic transplant2021EngraftmentAcute myeloidSurvivalClinical trialsTherapyCancersHematologic malignanciesCancerBloodFludarabineLeukemiaDonor'sTherCordCaregivers
Bone43
Chemotherapy10
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • Ablative (myeloablative) treatment -- High-dose chemotherapy, radiation, or both are given to kill any cancer cells. (medlineplus.gov)
  • Reduced intensity treatment, also called a mini transplant -- Lower doses of chemotherapy and radiation are given before a transplant. (medlineplus.gov)
  • Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. (medlineplus.gov)
  • After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make normal blood cells. (medlineplus.gov)
  • A stem cell transplant is usually done after chemotherapy and radiation is complete. (medlineplus.gov)
  • Drugs used in chemotherapy, such as busulfan, fludarabine phosphate and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mdanderson.org)
  • Before the 1980s, fewer than 100 cases of PJP were reported annually in the United States, occurring in patients who were immunosuppressed (eg, cancer patients receiving chemotherapy and solid-organ transplant recipients receiving immunosuppressants). (medscape.com)
  • High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • High-dose melphalan followed by autologous stem cell transplant after induction has been associated with superior event-free survival compared with chemotherapy and is considered the preferred approach. (medscape.com)
Outcomes4
  • However, several transplant registry studies in United States and Europe have confirmed comparable survival outcomes between matched unrelated and haploidentical transplants. (mhmedical.com)
  • Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. (cdc.gov)
  • This site provides information for patients and their families ranges from data about transplant outcomes to best practices in follow-up care for patients post-transplant. (myeloma.org)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
Post-transplant cyclophosphamide1
  • This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant. (mdanderson.org)
Curative5
Recipients5
  • Infl uenza is a major cause of illness and death in patients zanamivir, use of concomitant antimicrobial therapy, and with hematologic malignancy and in hematopoietic cell intravenous immunoglobulin was determined by the treat- transplant (HCT) recipients. (cdc.gov)
  • Hence the outcome of reduced intensity HSCT with lymphodepleting antibodies in older patients with intermediate/high-risk hematological malignancies appears comparable to that obtained with fully ablative transplantation in younger patients, even when these older recipients lack HLA-identical sibling donors. (nih.gov)
  • Younger donors, male donors, fathers rather than mothers, and first-degree to second-degree donors are preferred graft sources for recipients of haploidentical transplants. (mhmedical.com)
  • The BMT Thrivers event at Memorial Sloan Kettering celebrates Blood Marrow Transplant recipients and their return to health. (mskcc.org)
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
HSCT10
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Due to advances in transplant approaches and supportive care, the use of HSCT is increasing worldwide. (hindawi.com)
  • Despite such a progress, HSCT is still associated with substantial transplant-related mortality (TRM). (hindawi.com)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
Patients28
  • All patients received high-dose etoposide (60 mg/kg) and allogeneic stem cell transplantation following the TBI. (nature.com)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. (nih.gov)
  • We studied three SCID patients who were transplanted with unmodified mobilized peripheral blood from HLA-identical family sex-mismatched members. (nih.gov)
  • In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. (nih.gov)
  • Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. (nih.gov)
  • In all, 16 patients had high-risk disease, including 12 with active malignancy at the time of transplant. (nih.gov)
  • Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
  • Patients with monoclonal gammopathy of unknown significance, smoldering MM, plasma cell leukemia and amyloidosis were excluded. (scielo.br)
  • Haploidentical stem cell transplantation (HaploSCT) from a first-degree related mismatched haplotype donor (siblings, children, parents) extends the application of this lifesaving treatment to a large proportion of patients with high-risk hematologic malignancies who otherwise do not have a suitable human leukocyte antigen (HLA)-matched donor. (mhmedical.com)
  • Patients with CLL typically have a higher-than-normal white blood cell count, which is determined by a complete blood count (CBC). (medscape.com)
  • The risk of regretting transplantation was 17.5 percentage points (95% confidence interval, 5.5-29.7 percentage points) greater in patients who developed disease recurrence after HCT compared with patients who did not. (cdc.gov)
  • Conclusions: Among patients who underwent alloHCT and lived to 100 days, the majority did not report regretting their transplantation. (cdc.gov)
  • Hematopoietic stem cell transplantation can be considered in young patients with chronic myelogenous leukemia in chronic phase if a human leukocyte antigen (HLA)-matched donor is available. (medscape.com)
  • Complete normalization of hemoglobin (complete and major hematological response), is seen in no more than one third of patients, while the remaining continue to experience some degree of anemia (good and partial hematological responses), in some cases requiring regular red blood cell transfusions (minor hematological response). (frontiersin.org)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • Alkylator and nitrosourea therapy is usually deferred or reduced in patients who may require autologous stem cell collection, to avoid injury to the stem cells. (medscape.com)
  • All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitor and dexamethasone). (medscape.com)
  • Frailty score predicts outcome in transplant-ineligible patients with newly diagnosed myeloma and is incorporated into the staging criteria. (medscape.com)
  • [ 13 ] are the most active regimens for transplant-ineligible patients, although addition of the anti-CD38 monoclonal antibody daratumumab to these regimens to drive deeper response is likely to become the new standard of care. (medscape.com)
  • Visit for to learn about assistance for patients and their loved ones better understand blood and marrow transplantation and provides links to patient-focused marrow transplantation organizations. (myeloma.org)
  • Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. (bloodline.net)
  • The use of autologous transplant in Hodgkin's and non-Hodgkin's lymphoma has significantly improved the survivals of patients with relapsed disease. (bloodline.net)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • MSC co-culture with skin fibroblasts from mitochondrial disease patients rescued aberrant mitochondrial morphology from a fission state to a more fused appearance indicating an effect of MSC co-culture on host cell mitochondrial network formation. (frontiersin.org)
  • one of the patients reached the 30-month post-transplant mark in starkly improved health. (lww.com)
  • Those patients may be re-transplanted. (lww.com)
Cyclophosphamide1
Haploidentical transplantation1
Umbilical8
  • Umbilical cord blood transplant -- This is a type of allogeneic transplant. (medlineplus.gov)
  • Stem cells are removed from a newborn baby's umbilical cord right after birth. (medlineplus.gov)
  • Umbilical cord blood cells are very immature so there is less of a need for perfect matching. (medlineplus.gov)
  • This is when stem cells that are obtained from the bloodstream or umbilical cord of a donor are used for transplant into a patient. (differencebetween.net)
  • Umbilical cord blood stem cells are only used for transplant into children since there are not enough cells present to be of any use for transplant into an adult patient. (differencebetween.net)
  • A stem cell transplant is when stem cells are harvested from the bloodstream or the umbilical cord. (differencebetween.net)
  • Stem cell transplants involve cells that are taken out of the blood or umbilical cord. (differencebetween.net)
  • The purpose of this study is to examine the therapeutic efficacy of human umbilical cord mesenchymal stem/stromal cells (UMSCs) in treating congenital and acquired corneal opacity associated with the loss of collagen V. (molvis.org)
Allogeneic transplant1
  • Haploidentical transplant -- This is a type of allogeneic transplant, in which the donor is not completely matched with the recipient. (medlineplus.gov)
20211
Engraftment1
  • MSCs can promote host tissue repair through several different mechanisms including donor cell engraftment, release of cell signaling factors, and the transfer of healthy organelles to the host. (frontiersin.org)
Acute myeloid1
Survival3
Clinical trials2
Therapy1
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
Cancers3
Hematologic malignancies1
Cancer4
  • Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them. (mdanderson.org)
  • Our scientists pursue every aspect of cancer research-from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. (mskcc.org)
  • http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. (mayoclinic.org)
  • are a type of T cell that recognizes and kills abnormal cells (such as certain infected cells and cancer cells). (msdmanuals.com)
Blood22
Fludarabine1
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
Leukemia1
  • The killing of leukemia cells is proportional to the radiation absorbed dose. (nature.com)
Donor's2
  • The donor first has to be treated with G-CSF, and then the stem cells can only be harvested a couple of days after the donor since time is needed for the donor's body to form more stem cells and transport these cells into the bloodstream. (differencebetween.net)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
Ther1
Cord1
  • Previous work has shown that transplanted dissociated glial cells derived from neonatal rats can myelinate areas of the myelin deficient (md) rat spinal cord. (karger.com)
Caregivers1
  • This site provides information, referrals, and support by trained peer volunteers who are transplant survivors, caregivers, and donors. (myeloma.org)